



# Midkine promotes kidney injury in diabetic kidney disease by increasing neutrophil extracellular traps formation

Gaohong Liu<sup>1,2</sup>, Xiaojun Ren<sup>3</sup>, Yousong Li<sup>4</sup>, Han Li<sup>1</sup>

<sup>1</sup>Department of Nephrology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China; <sup>2</sup>Department of Nephrology, Shanxi Provincial People's Hospital, Taiyuan, China; <sup>3</sup>Department of Nephrology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China; <sup>4</sup>Department of Traditional Chinese Medicine, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China

**Contributions:** (I) Conception and design: All authors; (II) Administrative support: H Li; (III) Provision of study materials or patients: G Liu, X Ren; (IV) Collection and assembly of data: G Liu, X Ren, Y Li; (V) Data analysis and interpretation: G Liu, X Ren, Y Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Han Li. Department of Nephrology, Beijing Chao-Yang Hospital, Capital Medical University, No. 8 Gongti South Road, Chao-Yang District, Beijing 100020, China. Email: hanli@ccmu.edu.cn.

**Background:** We sought to investigate the role of midkine (MK) on neutrophil extracellular trap formation (NETosis) and diabetic kidney disease (DKD) progression.

**Methods:** The expression of MK and NETosis in the renal tissue of DKD patients was examined by immunohistochemistry and immunofluorescence, respectively. Neutrophils extracted from mouse bone marrow by gradient centrifugation were treated with MK for this *in-vitro* study. A mouse diabetes model was induced by a high-fat diet combined with an intraperitoneal injection of streptozocin (STZ). Antisense oligodeoxynucleotide (ODN) for MK inhibition was administered via tail vein injection.

**Results:** We found that the expression of MK was increased in the kidney tissue of DKD patients. Additionally, a greater number of neutrophils were primed toward NETosis in the kidney tissue of DKD patients, which was manifested by the increased expression of NETosis biomarkers citrullinated histone H3 (H3Cit) and myeloperoxidase (MPO). *In vitro*, MK treatment concentration-dependently increased neutrophil proliferation (cell counting kit-8). Further, western blot and enzyme-linked immunosorbent assays showed that MK (100 ng/mL) significantly promoted NETosis and the expression of inflammatory factors interleukin (IL)-1 and IL-6 secretion in high-glucose treated neutrophils. In the mouse diabetes model, MK promoted the pathological damage and fibrosis of kidney tissue, as demonstrated by the reversion of the pathological damage and fibrosis by the MK antisense ODN [diabetes mellitus (DM) + MK – ODN] treatment. Additionally, the inhibition of MK reduced the formation of NETs.

**Conclusions:** MK promotes DKD progression by increasing NETosis.

**Keywords:** Diabetic kidney disease (DKD); midkine (MK); NETosis; neutrophils

Submitted Apr 07, 2022. Accepted for publication May 31, 2022.

doi: 10.21037/atm-22-2382

View this article at: <https://dx.doi.org/10.21037/atm-22-2382>

## Introduction

It was estimated that the global prevalence of diabetes in individuals aged 20–79 years in 2021 was 10.5% (536.6 million people), and will rise to 12.2% (783.2 million) in 2045 (1). Diabetic kidney disease (DKD) is the most

common microvascular complication of diabetes (2,3). It is the primary cause of the end-stage renal disease (ESRD) in European and American countries, and the 2nd cause of ESRD in China (4). In 2016, a multi-center study in China confirmed that DKD had surpassed chronic glomerulonephritis to become the 1st cause of

hospitalization for chronic kidney disease patients in China (5). DKD was characterized by proteinuria, thickening of the renal basement membrane, expansion of mesangial area, continuous renal fibrosis, and progressive renal hypofunction (6,7). The diminished renal function caused by DKD would not only shorten the life expectancy but also increase the risk of cardiovascular disease of patients, which will seriously affect the quality of life (8). However, there is no specific effective drug for the treatment of DKD presently. The pathogenesis of DKD was complex and involved many factors, including hemodynamic disorder, glucose and lipid metabolism disorders, advanced glycosylation end products (AGEs), advanced glycosylation end products (ALEs) accumulation, renin-angiotensin-aldosterone system (RAAS) activation, oxidative stress reaction, and so forth (9). Thus, an in-depth exploration of the pathogenesis of DKD is of important clinical significance if effective treatments are to be developed.

In recent years, the role of chronic inflammation in the progression of DKD has been the subject of increasing research (10). Neutrophils are the largest number of white blood cells in the peripheral blood and play an extremely critical role in the immune response. In 2004, Brinkmann *et al.* (11) discovered for the first time that activated neutrophils participate in capturing and killing pathogenic bacteria by releasing neutrophil extracellular traps (NETs). NETosis refers to the way neutrophils form NETs. NETs are a new pathway of neutrophil death that are different from apoptosis and necrosis. NETs are composed of DNA and various proteins including neutrophil elastase, citrullinated histones (CitH3), neutrophil elastase (NE), myeloperoxidase (MPO), and other proteins. NETs wrap and kill invading pathogens (12). However, NETosis is also a “double-edged sword”. If NETs are over-formed or not cleared in time, this gummy network structure, which is rich in hydrolase and DNA, can attach to the vascular endothelium, causing endothelial cell apoptosis and tissue damage. At the same time, it can also induce autoimmunity by releasing endogenous danger signals (13). Research has shown that NETosis promotes the progression of various kidney diseases, including post-infection glomerulonephritis, renal ischemia-reperfusion injury, antineutrophil cytoplasmic antibody (ANCA)-related vasculitis, lupus nephritis, anti-basement membrane nephropathy, and membranous glomerulonephritis through direct pro-inflammatory effects aseptic necrotizing inflammation, thrombosis, and the generation of autoantibodies against NETs (14). Additionally, NETosis

has also been reported to facilitate the occurrence and development of diabetes and its complications (15). Neutrophils are critical component of the innate immune system which offer frontline defense against pathogens through a variety of potent effector functions. Uncontrolled activation of neutrophils leads to the production of reactive oxygen species (ROS) and NETs that play important roles in type-2 diabetes and atherosclerosis. One possibility is the activation of Toll-like receptors (TLRs) from the byproducts on persistent sterile inflammation (16). However, the mechanism of NETosis in the pathogenesis of DKD needs to be further explored.

Midkine (MK) is a heparin-binding cytokine, also known as a growth factor, with a molecular weight of 13 kD, which has a number of functions, including the chemotaxis of inflammatory cells, anti-damage, and anti-apoptosis (17). Under physiological conditions, the MK gene is highly expressed in embryonic epithelial-mesenchymal tissues and nerve tissues; however, it is almost never expressed in other parts, including brain, heart, liver, lungs, and fatty tissue, except the kidney, testis, stomach, and small intestinal epithelium in adult tissues (18). Upon binding to its receptors, MK activates multiple signal pathways to regulate cell survival and migration, epithelial-to-mesenchymal transition, and oncogenesis (19). Recent research has shown that in the heart tissue of myocarditis patient and mouse models, MK induces neutrophil migration and NETosis formation through the low-density lipoprotein receptor 1, and promotes the occurrence of myocarditis. Targeting MK protects heart function by reducing the formation of NETosis (20). Further, MK is closely related to a variety of kidney diseases (21). It was reported that MK is a biomarker for early detection of diabetic nephropathy in children with type 1 diabetes mellitus (T1DM) (22). In *Mdk*<sup>-/-</sup> mice, nephropathy was strikingly milder than *Mdk*<sup>+/+</sup> mice after Streptozotocin injection (23). Meanwhile, MK promoted tubulointerstitial inflammation in the diabetic mouse model by activating the MCP-1 signaling pathway (24). However, it is unclear whether MK participates in the occurrence and progression of DKD by promoting NETosis. This study sought to investigate whether MK participates in DKD through NETosis using *in-vitro* kidney tissue samples from DKD patients and cell cultures, and *in-vivo* type 2 diabetes mouse models, and to provide a new theoretical basis for the prevention and treatment of clinical DKD. We present the following article in accordance with the ARRIVE reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-2382/rc>).

## Methods

### *Clinical samples collection*

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The ethics committee of Shanxi Provincial People's Hospital (Taiyuan, China) granted approval for the experiment procedure (No. 2022-58). The patients are all from Shanxi Provincial People's Hospital. Renal tissue biopsy samples were obtained from 10 DKD patients and adjacent normal renal tissues of 10 renal cancer patients via nephrectomy were used as controls. The kidney tissues were subject to pathological examination, immunohistochemistry (IHC), and immunofluorescence (IF) staining. All the patients provided written informed consent for this study.

### *Neutrophil isolation and identification*

Animal experiments were carried out following a protocol approved by the Animal Ethics Committee of Shanxi Bethune Hospital (No. SBQKL-2021-028), in compliance with Shanxi Bethune Hospital guidelines for the care and use of animals. A protocol was prepared before the study without registration. The bone marrow of the femur and tibia was collected from healthy male C57BL/6 mice and washed with 1xhanks balanced salt solution (HBSS, containing 1% bovine serum albumin (BSA), without  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$ ). Next, the filtrate was collected and centrifuged for 10 min  $\times$  500 g at 4 °C to obtain the bone marrow cells. The neutrophils were isolated from the bone marrow by density gradient centrifugation as previously described (25). Flow cytometry was performed to identify isolated neutrophils ( $\text{Ly6G}^+\text{CD11b}^+$ ). The antibodies used were anti-mouse Ly6G (clone 1A8, 127625, BioLegend), and anti-mouse/human CD11b (clone M1/70, 101204, BioLegend). Following 1 h of incubation at 4 °C, the samples were run on a BD FACSCanto II flow cytometer. Subsequently, the neutrophils were seeded into 4-well cell culture sections at a density of  $2 \times 10^5$ /well and incubated for 1 h. The cells were fixed with 95% ethanol for 20 min, stained with wright staining solution (Solarbio, China), and observed using a microscope (Olympus Corporation, Japan).

### *CCK-8 assays*

The neutrophils were cultured in 96-well plates with an inoculation density of  $1 \times 10^4$ /well for 24 h at 37 °C in 5% carbon dioxide. Next, the neutrophils were cultured for a

further 24, 48, or 72 h after being treated with different concentrations of MK (CYT-178, ProSpec, Israel). The cell counting kit-8 (CCK-8, BS350B, Biosharp, China) was used to determine the proliferation of cells according to the operating manual. The absorbance was recorded at 450 nm by a microplate reader (ThermoFisher Scientific, USA).

For the *in-vitro* experiment, the neutrophils were divided into the following 6 groups: (I) the normal-glucose (NG) group (which received 5.5 mM of D-glucose); (II) the NG + MK group (which received 5.5 mM of D-glucose + 100 ng/mL of MK); (III) the mannitol group (MG; a hyperosmolar control; which received 5.5 mM of D-glucose + 25 mM of mannitol); (IV) the MG + MK group (which received 5.5 mM of D-glucose + 25 mM of mannitol + 100 ng/mL of MK); (V) the high-glucose (HG) group (which received 25 mM of D-glucose); and (VI) the HG + MK group (which received 25 mM of D-glucose + 100 ng/mL of MK). The concentration of MK used in cell experiment referenced previously published article (26).

### *Animals experiment*

Healthy male C57BL/6 mice (weighing 15–25 g and aged 6 weeks old) were provided by the Experimental Animal Center of Shanxi Medical University. The temperature and relative humidity of the rearing room was  $25 \pm 2$  °C and 40% to 60%, respectively. All the mice were supplied with standard diet water ad libitum.

The 30 mice were randomly divided into the following 3 groups (n=10): (I) the normal control (NC) group; (II) the diabetes mellitus (DM) group; and (III) the DM + MK antisense oligodeoxynucleotide group (DM + MK – ODN). The DKD model with DM was induced by a high-fat diet for 4 consecutive weeks (60 kcal% Fat, D12492, Dowsontec, China), and an intraperitoneal injection of 40 mg/kg/d of STZ (Sigma Aldrich, USA) (dissolved in citrate buffer, pH 4.0) after overnight fasting for 3 consecutive days (27). Mice with fasting blood glucose (FBG) levels  $\geq 11.1$  mM were regarded as type 2 diabetic mice 7 days after injection (28). From the 9th week, 20  $\mu\text{L}$  of MK antisense oligodeoxynucleotide (ODN; 1 mM, 5'-AGGGCGAGAAGGAAGAAG-3', corresponding to bases 15 to 32 in MK complementary DNA) and 30  $\mu\text{L}$  of Plus reagent (Invitrogen) were mixed in phosphate-buffered saline (PBS; total: 100  $\mu\text{L}$ ). Next, this mixture was administered via a tail vein injection in the DM + MK – ODN group once a week for 8 consecutive weeks (29). The mice in the DM group were injected with equivalent

volume of Plus reagent (Invitrogen) and PBS. Additionally, mice in the NC group were supplied with a normal diet and the same volume of citrate buffer and saline. Urine was accurately collected for 24 h in the metabolic cage 1 day before tissue collection. Blood was taken from the orbit of the mice under anesthesia with sodium pentobarbital (40 mg/kg). Serum and urine were stored at  $-80^{\circ}\text{C}$  for further assays. Kidneys were collected for the histological analysis and western blot assays.

### **Renal pathological examination**

The kidney tissues of the clinical specimens and DM mice were dissected, fixed, dehydrated, embedded, and cut into 3- $\mu\text{m}$  sections, stained with hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), and Masson, separately. The stained sections were analyzed using a digital trinocular camera microscope (Panthera, Motic China Group Co., Ltd., China) and image analysis software Image-Pro Plus 6.0 (Media Cybernetics, USA).

### **General biochemical parameters**

At 24 h, urine albumin was measured by radioimmunoassay (Furui, Beijing, China). The levels of FBG, serum creatinine (Scr), and urine creatinine (Ucr) were measured with an automatic biochemical analyzer (model 7150; Hitachi, Tokyo, Japan), and the level of the urine albumin/creatinine ratio (UACR) was analyzed (in mg albumin/g of creatinine).

### **ELISA**

The levels of NE, MK, interleukin (IL)-1, and IL-6 from the DM mouse serum samples or neutrophil supernatant were examined using the ELISA kit (ZhuoCai Biological Technology, China) in accordance with the manufacturer's instructions. The serum samples were added into NE, MK, IL-1, or IL-6 pre-coated wells. Next, the anti-hamster (NE, MK, IL-1, or IL-6) monoclonal antibodies were added, respectively. These antibodies were labeled with biotin and combined with Streptavidin-horseradish peroxidase (HRP) to form an immune complex. After the immune complex was treated as described, the absorbance of the wells was measured with a microplate reader (SpectraMAX Plus384, USA) at a 450-nm wavelength to calculate the sample concentration in accordance with the

manufacturer's instructions.

### **Western blot analysis**

Total protein was collected from the kidneys of the DM mice or neutrophils using a Total Protein Extraction Kit (BC3711, Solarbio) and quantified with a BCA protein quantification kit (ab102536, Abcam, Cambridge, MA, UK) in accordance with the operating manual. Protein samples were electrophoresed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) at 80 V for 30 min and 110 V for 50 min and then transferred to a polyvinylidene fluoride (PVDF) membrane electrically. The membranes were pre-blocked with Tris-buffered saline solution/ 0.1% Tween (TBST; Sigma Aldrich, USA; containing 5% skim milk) for 1 h at room temperature and incubated with primary myeloperoxidase (MPO) antibody (1:1,000, ab208670, Abcam, Cambridge, MA, UK), histone H3 (citrulline R2 + R8 + R17) antibody (1:1,000, ab5103, Abcam, Cambridge, MA, UK),  $\alpha$ -smooth muscle actin antibody ( $\alpha$ -SMA; 1:1,000, 19245, Cell Signaling, Danvers, MA), collagen I antibody (1:1,000, ab34710, Abcam, Cambridge, MA, UK), collagen IV antibody (1:1,000, ab6586, Abcam, Cambridge, MA, UK), fibronectin 1 (FN1; 1:1,000, 2413, Cell Signaling, Danvers, MA), and  $\beta$ -actin antibody (1:1,000, AC026, Abclonal, USA) at  $4^{\circ}\text{C}$  overnight. After washing the membrane with TBST, the membrane was hatched with goat-anti-rabbit immunoglobulin G (IgG) (H + L)-HRP (1:10,000, ab6721, Abcam, Cambridge, MA, UK) for 1 h at  $37^{\circ}\text{C}$  and then washed with TBST. The visualization of the reaction was developed by 3,3-diaminobenzidine (DAB; Sigma, USA) for 10 min.

### **IHC**

The kidney samples of the clinical specimens and DM mice were fixed with 4% paraformaldehyde at room temperature for 5 h before being embedded in paraffin. Next, the paraffin sections (5  $\mu\text{m}$ ) were used for the IHC assays. The sections were stained by rabbit polyclonal MK antibody (1:100, bs-1849R, Bioss, China). Biotinylated goat anti-rabbit IgG (SP9001, ZsBio, China) was used as a secondary antibody. The stained sections were analyzed using the digital trinocular camera microscope (Panthera, Motic China Group Co., Ltd., China) and image analysis software Image-Pro Plus 6.0 (Media Cybernetics, USA).

### *IF of the formation of NETosis*

Paraffin sections of kidney tissues from the clinical specimens and DM mice were dewaxed and hydrated before staining. The sections were incubated in QuickBlock™ Blocking Buffer (Beyotime Biotechnology, Jiangsu, China, P0260) for 30 min at room temperature. The sections were then incubated with MPO antibody (Abclonal, China, A1374, 1:100) or H3Cit antibody (Biyuntian, China, AF0009, 1:100) at 4 °C overnight and washed 3 times with PBS. Fluorescein isothiocyanate (FITC) goat anti-rabbit IgG or Cy3-conjugated goat anti-mouse IgG was used as a secondary antibody. 4',6-diamidino-2-phenylindole (DAPI; Abcam, ab104139; 1/2,000) was added dropwise into the sections for 5 min. The staining was observed under a fluorescence microscope BX53 (Olympus, Tokyo, Japan) at ×100 magnifications.

### *Statistical analysis*

All the results are presented as the mean ± standard error of the mean. Differences between 2 groups were analyzed using a Student's *t*-test, while differences between multiple groups were analyzed using a 1-way analysis of variance and Duncan's test using the SPSS 22.0 package (SPSS Inc. Chicago, IL, USA).

## **Results**

### *MK expression and NETosis were detected in the diseased kidneys of the DKD patients*

Pathological changes in DKD were analyzed by H&E, Masson, and PAS staining. The H&E, Masson, and PAS staining revealed that compared to the control patients who had normal tubular and glomeruli architecture (see *Figure 1A-1D*), there was glomerular necrosis, tubular epithelial thinning, and thickened basement membranes in the kidney tissues of the DKD patients (see *Figure 1A*). Additionally, the degree of renal fibrosis (see *Figure 1B*) and the content of the PAS-positive area (see *Figure 1C,1D*) were significantly increased in the kidney tissues of the DKD patients. IHC was also examined, and the results showed that the level of MK was indeed higher in the DKD than the normal kidneys (see *Figure 1E,1F*). IF was performed to examine the expression of the NETosis biomarkers H3Cit and MPO. The results revealed the enhanced staining of H3Cit and MPO in the DKD kidneys compared to the

normal kidneys (see *Figure 1G*). Thus, MK expression and NETosis may play an important role in the induction of nephropathy in DKD patients.

### *Isolation and identification of neutrophils*


We first isolated neutrophils for the *in-vitro* experiments. The neutrophils were separated from the bone marrow of healthy male mice. The neutrophils were defined as CD11b<sup>+</sup>Ly6G<sup>+</sup> cells by flow cytometry (see *Figure 2A*). The neutrophils were then identified by Wright staining under microscope (100× oil lenses). The microscopic images were typical of neutrophils; the horseshoe-shaped nucleus was stained blue-purple, and the cytoplasm remained light red (see *Figure 2B*).

### *Toxic effect of MK on neutrophils*


To examine the effect of MK on neutrophils, the cell viability of neutrophils treated with different concentrations of MK (10, 50, 100, and 200 ng/mL) at different durations (0, 24, 48, and 72 h) was examined by CCK-8 assays. As *Figure 3A*, shows there were no significant differences in the cell viability of the neutrophils treated with 10, 50, 100, and 200 ng/mL MK at 0 and 24 h (see *Figure 3A*); however, at 48 and 72 h, the cell viability of the neutrophils treated with 100 and 200 ng/mL of MK was significantly higher than those treated with 10 and 50 ng/mL of MK (see *Figure 3A*). Further, the cell viability of the neutrophils treated with 100 ng/mL of MK was the highest among the concentrations of MK at all 4-time points (see *Figure 3A*). Thus, we optimized the effective treatment concentration of MK and the duration at 100 ng/mL for 48 h.

### *MK increased neutrophil secretion of the inflammatory cytokines in vitro*


In comparison to the results for the supernatant of the neutrophils cultured in conditions of NG or mannitol, the levels of neutrophil secretion of IL-1 and IL-6 was notably increased when the cells were cultured in the presence of high glucose medium (25 mM of D-glucose; see *Figure 3B*). Notably, MK treatment further elevated the levels of both IL-1 and IL-6 under the normal-glucose, mannitol, and high-glucose conditions (see *Figure 3B*). Thus, MK accelerated inflammatory cytokine secretion from neutrophils.



**Figure 1** MK expression and NETosis were elevated in the diseased kidneys of the DKD patients. Kidney sections were stained with H&E (A), Masson (B), and PAS (C,D). The magnification is  $\times 200$  or  $\times 400$ . (A) Green arrow indicates glomerular necrosis; yellow arrow indicates thinning of tubular epithelial cells; blue arrow indicates glomerular stromal hyperplasia. (B) Yellow arrows indicate fibrosis with blue staining. (C) Yellow arrows heads point to PAS positivity. (E,F) The expression of MK in kidneys was determined by IHC (yellow arrows, positive IHC). The magnification is  $\times 400$ . (G) The protein expression of H3Cit and MPO was determined by IF. The magnification is  $\times 400$ . The means  $\pm$  standard deviations of 6 independent samples are shown. \*\* $P < 0.01$ . MK, midkine; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff; IHC, immunohistochemistry; IF, immunofluorescence.



**Figure 2** Isolation and identification of neutrophils. The bone marrow of healthy male mice was collected to extract neutrophils by gradient centrifugation. (A) Analyses of Ly6G CD11b surface expression on neutrophils by flow cytometry. (B) The morphology of separated neutrophils was observed using a microscope after Wright staining. The magnification is  $\times 100$ .




**Figure 3** MK increased inflammatory cytokine secretion and NETosis *in vitro*. (A) Neutrophils were treated with 10, 50, 100, and 200 ng/mL MK at 0, 24, 48 and 72 h. Next, the CCK-8 kit was used to examine the cell viability of neutrophils. (B) The levels of IL-1 and IL-6 in the cell supernatant was examined using ELISA. (C) The levels of NE in the cell supernatant was detected using ELISA. (D,E) The protein expression of H3Cit and MPO was determined by western blot normalized against  $\beta$ -actin. The means  $\pm$  standard deviations of 3 independent samples are shown.  $^{\#}P < 0.05$  vs. NG group,  $^{*}P < 0.05$  vs. MG group,  $^{\#}P < 0.05$  vs. NG/MG/HG group. NG, normal-glucose; MG, mannitol group; HG, high-glucose; CCK-8, cell counting kit-8; MK, midkine; ELISA, enzyme-linked immunosorbent assay; NE, neutrophil elastase; CitH3, citrullinated histones; MPO, myeloperoxidase; IL-1, interleukin-1; IL-6, interleukin-6; ns, no significant.

### MK promoted NETosis *in vitro*

The effect of MK on neutrophil NETosis was assessed by ELISA assays. The results showed that MK treatment prominently increased the level of NE in the high glucose-

induced neutrophil group compared to the NG and mannitol groups (see *Figure 3C*). Additionally, the Western blot results showed that MK notably elevated H3Cit and MPO protein levels under the normal-glucose, mannitol,



**Figure 4** MK caused kidney damage in the DKD model. (A) The serum levels of FBG, Scr, and UACR were detected using biochemical methods. The kidney sections were stained with H&E (B), Masson (C), and PAS (D,E). The magnification is  $\times 100$  or  $\times 400$ . (B) The renal glomerulus exhibited thickening of the basement membrane and formation of interlayers (yellow arrows). (C) Yellow arrows indicate fibrosis with blue staining. (D) Yellow arrows heads point to PAS positivity. The means  $\pm$  standard deviations of 6 independent samples are shown. \* $P < 0.05$ , \*\* $P < 0.01$ . DKD, diabetic kidney disease; NC, normal control; DM, diabetes mellitus; MK, midkine; ODN, oligodeoxynucleotide; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff.


and high-glucose culture conditions, respectively (see *Figure 3D,3E*). These data demonstrated that MK promoted the NETosis of neutrophils *in vitro*.

#### **MK caused kidney injury in the DKD model**

We examined the role of MK in diabetic kidney damage *in vivo*, using MK antisense ODN to counteract the expression of MK in the mouse DKD model. The ELISA

analysis of the kidney function indexes showed that the levels of FBG, Scr, and UACR were all increased in the serum of the diabetic mice, which was significantly reduced by MK antisense ODN treatment (see *Figure 4A*). The H&E staining showed that the kidney tissues of the diabetic mice had a blurred glomerular structure in the cortex area, a swollen glomerular, and a thickened basement membrane, and serous-fibrous exudate was observed in the lumen of some renal tubules. The MK antisense ODN treatment





**Figure 5** Expression of fibrosis-associated proteins in the kidney tissues of diabetic mice. A Western blot analysis was performed to examine the fibrosis-associated proteins  $\alpha$ -SMA, Collagen I, Collagen IV, and FN1 in the kidneys of diabetic mice. The means  $\pm$  standard deviations of 6 independent samples are shown. \* $P < 0.05$ , \*\* $P < 0.01$ . NC, normal control; DM, diabetes mellitus; MK, midkine; ODN, oligodeoxynucleotide; FN1, fibronectin 1.

significantly reduced these pathological changes in the kidney tissues of the diabetic mice (see *Figure 4B*). Kidney fibrosis was assessed by Masson staining. As *Figure 4C* shows, severe fibrosis was observed in the kidneys of the diabetic mice as assessed by Masson staining (see *Figure 4C*), which was significantly ameliorated by the MK antisense ODN treatment. Similarly, the PAS staining showed a significantly increased PAS stain positive area in the kidney tissues of the diabetic mice, while the MK antisense ODN treated mice showed a prominent decrease of PAS staining compared to the non-treated diabetic mice (see *Figure 4D,4E*). Further, the western blot results showed that the levels of fibrosis-associated proteins  $\alpha$ -SMA, Collagen I, Collagen IV, and FN1 were all increased in the kidneys of the diabetic mice, but were all reduced by the MK antisense ODN treatment (see *Figure 5*). All these results demonstrated that MK caused kidney injury in diabetic mice.


### *MK inhibited inflammatory factor secretion and the formation of NETosis in vivo*

To further confirm the effect of MK on NETosis and the inflammatory cytokine secretion, the serum levels of IL-1 and IL-6 were analyzed in an *in-vivo* experiment in 3 mouse experiment groups; that is, the NC, DM, and DM + MK – ODN groups. The results showed that the serum levels of IL-1 and IL-6 were significantly increased but were reduced by the MK antisense ODN treatment in diabetic mice (see *Figure 6A*). Additionally, the serum levels of MK and NE were dramatically increased but were also significantly decreased by the MK antisense ODN treatment in diabetic mice (see *Figure 6A*). Moreover, the IHC results showed that the average optical density of MK was consistent with the ELISA results (see *Figure 6B,6C*). The protein levels of H3Cit and MPO were elevated in diabetic mice but were reduced by the MK antisense ODN treatment (see *Figure 6D,6E*). Similarly, the IF results also showed an increase of NETosis in the diabetic mice, which was also significantly reduced by the MK antisense ODN treatment (see *Figure 6F,6G*). All these results showed that MK stimulated inflammation and NETosis in the kidney tissues of the diabetic mice.

### Discussion

DKD is the main complication of diabetes (2). It is extremely important to elucidate the molecular mechanism and the pathogenesis of DKD to identify the key target for both the diagnosis and treatment of DKD. In this study, we found that MK expression and NETosis were increased in the kidney tissues of DKD patients. Our study proved that MK caused kidney functional and histological injuries in DKD patients by promoting NETs.

Neutrophils are the main innate immune cells of the body's inflammatory response (30). However, the long-term persistence of neutrophil infiltration can cause tissue damage, which is closely related to the occurrence and development of many human diseases, such as diabetes mellitus (DM) and its complications (31). Previous study implied that diabetes-induced microvascular complications delays wound healing by activating NETosis in *Padi4<sup>-/-</sup>* mice (15). Meanwhile, NETosis is considered to be associated with the development of human diabetic foot ulcers. NETosis promoted NLRP3 inflammasome activation and IL-1 $\beta$ -dependent exacerbation of inflammation in diabetic foot ulcers (32). The production of



**Figure 6** MK increased inflammatory cytokine secretion and NETosis *in vivo*. (A) The serum levels of MK, NE, IL-1 and IL-6 were examined by ELISA; (B,C) the expression of MK in the kidneys was determined by IHC ( $\times 400$ ). (D,E) The protein expression levels of H3Cit and MPO were determined by western blot. The data were expressed after being normalized to  $\beta$ -actin. (F,G) The formation of NETosis in the kidney tissue was tested by IF ( $\times 400$ ). The means  $\pm$  standard deviations of 6 independent samples are shown. \* $P < 0.05$ . NC, normal control; DM, diabetes mellitus; MK, midkine; ELISA, enzyme-linked immunosorbent assay; IL-1, interleukin-1; IL-6, interleukin-6; NE, neutrophil elastase; CitH3, citrullinated histones; MPO, myeloperoxidase; IHC, immunohistochemistry; IF, immunofluorescence.

NETs is involved in cytokine-induced ocular inflammation in diabetic retinopathy mice (33). In the present study, neutrophils isolated from bone marrow were used for the *in-vitro* assessment of MK on NETosis in DKD. The *in-vitro* experiments revealed that 25 mM of D-glucose significantly accelerated the formation of NETs as shown by the dramatic increase in the levels of NE, MPO, and H3Cit, which was consistent with the previous results that showed that 25 mM of glucose enhanced the release of NETs and the NETosis rate more than 5 mM glucose *in vitro* and in type 2 diabetic patients (34). In type 1 DM patients, NETosis formation was significantly elevated, and may serve as a risk marker for diabetes-induced renal complications (15). Furthermore, we found that the formation of NETs was enhanced in kidney tissues in human and mice DKD samples, implying that NETs may play an important role in the DKD progression. Further study is needed to better elucidate the mechanism of NETs in DKD.

NE, MPO, and H3Cit are indispensable for the formation of NETs. NE can trigger histone degradation thereby causing DNA decondensation, but can also induce actin filament degradation, thus suppressing neutrophil movement (14). MPO can also migrate to the nucleus to help NE to degrade chromatin (14). In our study, MK dramatically boosted the formation of NETs under high-glucose conditions both *in vitro* and *in vivo*, based on the increased expression of NE, MPO, and H3Cit. It has been shown that MK induced neutrophil migration and NETosis formation in the heart tissue of myocarditis patients and mouse models (20). Kosugi *et al.* found that the expression of MK was significantly upregulated in tubule epithelial cells and mesangial cells stimulated by high glucose *in vitro*, and the expression of MK was detected in glomeruli, tubules and interstitium in the kidney biopsy specimens of DKD patients (23,24). In this study, we demonstrated that MK was significantly enhanced in the kidneys of DKD patients and diabetic mice, which was reversed by the knockdown of MK via the injection of MK antisense ODN. The systemic administration of MK antisense ODN has been reported to be absorbed in the proximal tubules (29). In line with previous studies, the dosage of MK antisense ODN employed in this study was 1 mg/kg, which produced the best and most effective effects with no obvious adverse effects in murine (29,35). It is also much lower than 10 mg/kg, which indicates its good tolerance in clinical trials (36,37).

MK has also been demonstrated to play an important role in the inflammatory process of DKD (23). It was

consistently observed in this study that MK significantly increases the level of IL-1 and IL-6 *in vitro* and *in vivo*, which indicates that MK might act as a direct activator of kidney inflammation in DKD (23,24). Further, in the DKD mice, MK increased Scr and UACR levels and promoted kidney injury, which is in line with results of a study using Mdk<sup>-/-</sup> mice (24). Several other studies have also revealed that the inhibition of MK prevented kidney damage in other conditions, including the onset of kidney disease in diabetes (23), 5/6 nephrectomy-induced hypertension (38), and ischemia-reperfusion (29,39). These results also suggest that the function of MK is closely related to the occurrence and progression of DKD.

## Conclusions

In summary, MK promoted NETosis and inflammatory cytokine secretion in both the *in-vivo* and *in-vitro* experiments in the current study. The suppression of MK using the MK antisense ODN significantly improved kidney function and reduced pathological damage in the DKD model. In brief, the results provided a molecular mechanism for the development inhibition of MK as a clinical treatment for DKD.

## Acknowledgments

**Funding:** This Research Project was supported by the Natural Science Foundation of Shanxi Province (No. 201901D211518), the Shanxi Scholarship Council of China (No. 2020-174), and the 136 Special Fund of Shanxi Provincial People's Hospital (No. sz2019017).

## Footnote

**Reporting Checklist:** The authors have completed the ARRIVE reporting checklist. available at <https://atm.amegroups.com/article/view/10.21037/atm-22-2382/rc>

**Data Sharing Statement:** Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-2382/dss>

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-2382/coif>). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all

aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The ethics committee of Shanxi Provincial People's Hospital (Taiyuan, China) granted approval for the experiment procedure (No. 2022-58). All the patients provided written informed consent for this study. Animal experiments were carried out following a protocol approved by the Animal Ethics Committee of Shanxi Bethune Hospital (No. SBQKL-2021-028), in compliance with Shanxi Bethune Hospital guidelines for the care and use of animals.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

- Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* 2022;183:109119.
- Schechter M, Leibowitz G, Mosenzon O. Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial. *Ann Transl Med* 2020;8:1698.
- Yamazaki T, Mimura I, Tanaka T, et al. Treatment of Diabetic Kidney Disease: Current and Future. *Diabetes Metab J* 2021;45:11-26.
- Pugliese G. Updating the natural history of diabetic nephropathy. *Acta Diabetol* 2014;51:905-15.
- Zhang L, Long J, Jiang W, et al. Trends in Chronic Kidney Disease in China. *N Engl J Med* 2016;375:905-6.
- Furuichi K, Shimizu M, Okada H, et al. Clinico-pathological features of kidney disease in diabetic cases. *Clin Exp Nephrol* 2018;22:1046-51.
- Chen C, Wang C, Hu C, et al. Normoalbuminuric Diabetic Kidney Disease. *Front Med* 2017;11:310-8.
- Fan Y, Yi Z, D'Agati VD, et al. Comparison of Kidney Transcriptomic Profiles of Early and Advanced Diabetic Nephropathy Reveals Potential New Mechanisms for Disease Progression. *Diabetes* 2019;68:2301-14.
- Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. *Clin J Am Soc Nephrol* 2017;12:2032-45.
- Jung SW, Moon JY. The role of inflammation in diabetic kidney disease. *Korean J Intern Med* 2021;36:753-66.
- Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. *Science* 2004;303:1532-5.
- Mutua V, Gershwin LJ. A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics. *Clin Rev Allergy Immunol* 2021;61:194-211.
- Vorobjeva NV. Neutrophil Extracellular Traps: New Aspects. *Moscow Univ Biol Sci Bull* 2020;75:173-88.
- Nakazawa D, Marschner JA, Platen L, et al. Extracellular traps in kidney disease. *Kidney Int* 2018;94:1087-98.
- Njeim R, Azar WS, Fares AH, et al. NETosis contributes to the pathogenesis of diabetes and its complications. *J Mol Endocrinol* 2020;65:R65-76.
- Keeter WC, Moriarty AK, Galkina EV. Role of neutrophils in type 2 diabetes and associated atherosclerosis. *Int J Biochem Cell Biol* 2021;141:106098.
- Cai YQ, Lv Y, Mo ZC, et al. Multiple pathophysiological roles of midkine in human disease. *Cytokine* 2020;135:155242.
- Campbell VK, Gately RP, Krishnasamy R, et al. Midkine and chronic kidney disease-associated multisystem organ dysfunctions. *Nephrol Dial Transplant* 2021;36:1577-84.
- Zhang ZZ, Wang G, Yin SH, et al. Midkine: A multifaceted driver of atherosclerosis. *Clin Chim Acta* 2021;521:251-7.
- Weckbach LT, Grabmaier U, Uhl A, et al. Midkine drives cardiac inflammation by promoting neutrophil trafficking and NETosis in myocarditis. *J Exp Med* 2019;216:350-68.
- Sato W, Sato Y. Midkine in nephrogenesis, hypertension and kidney diseases. *Br J Pharmacol* 2014;171:879-87.
- Metwalley KA, Farghaly HS, Gabri MF, et al. Midkine: Utility as a Predictor of Early Diabetic Nephropathy in Children with Type 1 Diabetes Mellitus. *J Clin Res Pediatr Endocrinol* 2021;13:293-9.
- Kosugi T, Yuzawa Y, Sato W, et al. Growth Factor Midkine Is Involved in the Pathogenesis of Diabetic Nephropathy. *Am J Pathol* 2006;168:9-19.
- Kosugi T, Yuzawa Y, Sato W, et al. Midkine Is Involved in Tubulointerstitial Inflammation Associated with Diabetic Nephropathy. *Lab Invest* 2007;87:903-13.
- Ubags NDJ, Suratt BT. Isolation and Characterization of Mouse Neutrophils. *Methods Mol Biol* 2018;1809:45-57.

26. Lackner I, Weber B, Baur M, et al. Midkine Is Elevated after Multiple Trauma and Acts Directly on Human Cardiomyocytes by Altering Their Functionality and Metabolism. *Front Immunol* 2019;10:1920.
27. Yan J, Wang C, Jin Y, et al. Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK/NOX4/PI3K/AKT pathway. *Pharmacol Res* 2018;130:466-80.
28. Gao YF, Zhang MN, Wang TX, et al. Hypoglycemic effect of D-chiro-inositol in type 2 diabetes mellitus rats through the PI3K/Akt signaling pathway. *Mol Cell Endocrinol* 2016;433:26-34.
29. Sato W, Takei Y, Yuzawa Y, et al. Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion. *Kidney Int* 2005;67:1330-9.
30. Guan H, Xie L, Ji Z, et al. Triptolide inhibits neutrophil extracellular trap formation. *Ann Transl Med* 2021;9:1384.
31. Patel AA, Ginhoux F, Yona S. Monocytes, Macrophages, Dendritic Cells and Neutrophils: An Update on Lifespan Kinetics in Health and Disease. *Immunology* 2021;163:250-61.
32. Lee MKS, Sreejit G, Nagareddy PR, et al. Attack of the Nets! Netosis Primes IL-1 $\beta$ -Mediated Inflammation in Diabetic Foot Ulcers. *Clin Sci (Lond)* 2020;134:1399-401.
33. Barliya T, Dardik R, Nisgav Y, et al. Possible Involvement of Netosis in Inflammatory Processes in the Eye: Evidence from a Small Cohort of Patients. *Mol Vis* 2017;23:922-32.
34. Menegazzo L, Ciciliot S, Poncina N, et al. NETosis is induced by high glucose and associated with type 2 diabetes. *Acta Diabetol* 2015;52:497-503.
35. Takei Y, Kadomatsu K, Matsuo S, et al. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. *Cancer Res* 2001;61:8486-91.
36. Gheibi-Hayat SM, Jamialahmadi K. Antisense Oligonucleotide (AS-ODN) Technology: Principle, Mechanism and Challenges. *Biotechnol Appl Biochem* 2021;68:1086-94.
37. Gagliardi M, Ashizawa AT. The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery. *Biomedicines* 2021;9:433.
38. Hobo A, Yuzawa Y, Kosugi T, et al. The growth factor midkine regulates the renin-angiotensin system in mice. *J Clin Invest* 2009;119:1616-25.
39. Sato W, Kadomatsu K, Yuzawa Y, et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. *J Immunol* 2001;167:3463-9.

(English Language Editor: L. Huleatt)

**Cite this article as:** Liu G, Ren X, Li Y, Li H. Midkine promotes kidney injury in diabetic kidney disease by increasing neutrophil extracellular traps formation. *Ann Transl Med* 2022;10(12):693. doi: 10.21037/atm-22-2382